Explorez tous les épisodes du podcast Healthcare Logic for Growth
| Titre | Date | Durée | |
|---|---|---|---|
| From Innovation to Revenue: How Healthcare Startups Turn a Great Product Into a Real Business | 15 Jun 2026 | 00:28:27 | |
Healthcare is full of great products that never became great businesses. In this first episode of the Healthcare Startup Revenue Series, we break down 4 of the structural barriers that accelerate performance:
Whether you’re still in your first year of commercial activity or stuck at early customers and unable to scale, this episode gives you a foundation to consider. Sources Referenced:
About Life Science Logic: Life Science Logic helps hospitals, HHAs, healthcare associations, small life science and healthcare companies go to market smarter, not more expensively. We combine commercial strategy, competitive intelligence, and planning with a disciplined, cost-conscious approach - delivering the rigor of a top-tier consultancy without the expanded overhead. The result? Our clients cut unnecessary spending, improve commercial efficiency, and give better performance earlier. Ready to spend less and perform better? Learn more at https://lifesciencelogic.com/ or reach us at Eric@lifesciencelogic.com.
Healthcare Logic for Growth · Life Science Logic · Eric@lifesciencelogic.com · © 2026 Life Science Logic | |||
| CMS Just Changed the Playbook for GLP-1...Consider the Following | 08 Jun 2026 | 00:28:05 | |
On May 1, 2026, the CMS BALANCE Model went live - opening the door for Medicaid agencies to begin enrolling in a new federal framework that expands GLP-1 coverage for obesity and metabolic disease. The Medicare GLP-1 Bridge follows on July 1st, giving Medicare Part D beneficiaries access to these drugs at $50 per month. Most of the conversation has focused on Novo Nordisk and Eli Lilly. This episode is for everyone else. We break down what BALANCE actually does, what the commercial ecosystem around it looks like for small pharma, biotech, digital health companies, home health agencies, and hospitals - and five specific actions you should be taking right now.
Sources Referenced in This Episode:
About Life Science Logic: Life Science Logic is a commercial strategy consultancy serving small life science, healthcare companies, and healthcare investors. We help founders and operators navigate go-to-market strategy, competitive intelligence, and commercial planning with the clarity and rigor that early-stage companies deserve and need. Learn more at https://lifesciencelogic.com/ or reach me at Eric@lifesciencelogic.com. Healthcare Logic for Growth · Life Science Logic · Eric@lifesciencelogic.com · © 2026 Life Science Logic | |||
| The Pilot Era Is Over - AI in Healthcare Has Crossed Into Real ROI, and Small Companies Are Running Out of Time to Catch Up | 01 Jun 2026 | 00:40:53 | |
Healthcare is deploying AI tools at more than twice the rate of the broader economy — and for the first time at meaningful scale, the ROI is real and documented. In this episode, we unpack the NVIDIA State of AI in Healthcare 2026 survey and this week's Healthcare IT News report on AI payment alignment to answer the question every small healthcare company is quietly asking: what does the AI inflection point actually mean for my business right now? We cover three real-world scenarios across six audience segments — hospitals, home health agencies, digital health startups, pharma, biotech, and healthcare associations — and close with six specific actions you can take this week.
Links:
About Life Science Logic: Life Science Logic is a commercial strategy consultancy serving small life science, healthcare companies, and healthcare investors. We help founders and operators navigate go-to-market strategy, competitive intelligence, and commercial planning with the clarity and rigor that early-stage companies deserve and need. Learn more at https://lifesciencelogic.com/ or reach me at Eric@lifesciencelogic.com. Healthcare Logic for Growth · Life Science Logic · Eric@lifesciencelogic.com · © 2026 Life Science Logic | |||
| The Medicaid Clock Is Already Ticking - What Every Small Healthcare Company Needs to Know Right Now | 25 May 2026 | 00:23:44 | |
On May 1st, 2026, Nebraska became the first state in the country to enforce Medicaid work requirements under the One Big Beautiful Bill Act - the sweeping federal law that includes nearly a trillion dollars in Medicaid cuts over ten years. Montana goes live July 1st. Iowa in December. And 43 states are federally required to follow by January 1st, 2027. In this episode, we break down what this means for small life science and healthcare companies, why the 2027 framing is the wrong planning frame, and five specific steps you should be taking right now to protect your revenue model and your commercial strategy. Sources Referenced in This Episode:
About Life Science Logic: Life Science Logic is a commercial strategy consultancy serving small life science, healthcare companies, and healthcare investors. We help founders and operators navigate go-to-market strategy, competitive intelligence, and commercial planning with the clarity and rigor that early-stage companies deserve and need. Learn more at https://lifesciencelogic.com/ or reach me at Eric@lifesciencelogic.com.
Healthcare Logic for Growth · Life Science Logic · Eric@lifesciencelogic.com · © 2026 Life Science Logic | |||
| The FDA Just Changed the Rules on Coverage - What Early-Stage Companies Need to Know. | 18 May 2026 | 00:14:37 | |
On April 23, 2026, the FDA and CMS announced the RAPID coverage pathway - a new program designed to cut the historically long gap between FDA device authorization and Medicare coverage from a year or more down to as little as two months. For early-stage life science device companies, this changes the commercial math. In this episode, we break down exactly what RAPID is, who qualifies, what it means for your launch strategy, and five specific steps you should be taking right now.
Sources Referenced in This Episode:
About Life Science Logic: Life Science Logic is a commercial strategy consultancy serving small life science, healthcare companies, and healthcare investors. We help founders and operators navigate go-to-market strategy, competitive intelligence, and commercial planning with the clarity and rigor that early-stage companies deserve and need. Learn more at lifesciencelogic.com or reach me at Eric@lifesciencelogic.com. CONNECT
| |||
| Biotech in 2026: The Capital, Clinical, and Commercial Triple Threat | 11 May 2026 | 00:13:57 | |
Biotech in 2026 is operating inside a Triple Threat. In this episode, we break down the three forces hitting simultaneously: capital pressure that now demands commercial readiness alongside clinical proof, clinical complexity that has turned trial design into a commercial decision, and commercial infrastructure gaps that show up at the worst possible moment - right when you need them most.
If you're leading an early-stage biotech, preparing for a Series B, or building out your first commercial team, this episode gives you an honest picture of the landscape and three clear actions you can take right now. WHY THIS MATTERS The playbook that worked three years ago no longer applies. Capital is concentrating at later stages and investors are asking commercial questions earlier. Payers are demanding evidence that gets built into trial design - not bolted on after approval. And the gap between FDA approval and commercial success has not gotten any shorter.
What's different in 2026 is that these three pressures are compounding each other. A weak commercial story makes fundraising harder. A misaligned trial design creates payer problems at launch. And a company that hasn't built commercial infrastructure in parallel with clinical development finds itself scrambling when the window opens. This episode is about seeing all three threats clearly - and acting on them now. WHAT WE COVER
YOUR GO FORWARD STRATEGY — 3 ACTIONS FROM THIS EPISODE 1 - Map your trial endpoints against payer coverage criteria - do this before your next protocol amendment, not after approval 2 - Build your one-page commercial narrative before your next investor meeting - your clinical story needs a commercial chapter 3 - Book one payer conversation this quarter - not to pitch, but to listen and learn what they'll actually need to see CONNECT
Healthcare Logic for Growth · Life Science Logic · Eric@lifesciencelogic.com · © 2026 Life Science Logic | |||
| The Honest State of Early-Stage Life Science in 2026: What Every Biotech, Pharma, MedTech, and Digital Health Company Is Really Up Against | 04 May 2026 | 00:17:02 | |
In this opening episode of the Early-Stage Life Science series, host Eric delivers an honest 30,000-foot assessment of what early-stage life science companies are up against in 2026. Not the headline version. The operational reality. WHY THIS EPISODE MATTERS The life sciences landscape looks strong from the outside - a recovering biotech index, active M&A, and AI transforming drug discovery at a real pace. But underneath those headlines, the environment for early-stage companies has quietly gotten harder. Capital is concentrating at later stages. The regulatory and reimbursement infrastructure hasn't gotten simpler. NIH funding pullbacks are creating upstream pressure that will shape the pipeline for years. The companies that succeed in this environment are the ones who see it clearly - not the ones running on optimism alone. This episode gives you that clear view - and a practical starting point for building commercial strategy that holds up under the pressure of 2026. WHAT WE COVER
GO FORWARD STRATEGY - 5 ACTIONS YOU CAN TAKE THIS WEEK 01 - Run a Commercial Readiness Check - Pull up your milestone map. Next to each clinical or regulatory milestone, write the commercial question it should be answering. If you can't write one, that's your gap. 02 - Map Capital Needs Against Commercial Milestones - Every dollar should be traceable to a milestone that strengthens your next raise. Line items that don't connect? That's your first efficiency opportunity. 03 - Have the Payer Conversation Earlier Than Feels Comfortable - If you haven't spoken with a payer medical director or pharmacy director about your product and evidence strategy, schedule that meeting this week. 04 - Audit Your Visibility in the Conversations That Matter - Identify the 3–5 conferences or forums where your key stakeholders gather. Is your company present and credible there? 05 - Name Your Biggest Commercial Blind Spot - Of the five challenge areas covered today, which one is your company most exposed to right now? Name it, write it down, and bring it to your next leadership meeting as a strategic priority.
CONNECT
Healthcare Logic for Growth · Life Science Logic · Eric@lifesciencelogic.com © 2026 Life Science Logic. All rights reserved. | |||
| Welcome to 'Healthcare Logic for Growth.' | 01 May 2026 | 00:02:20 | |
Actionable Insights and Go-Forward-Strategies for Hospitals, Clinics, Home Health, and Emerging Healthcare Companies Welcome to Healthcare Logic for Growth, the podcast from Life Science Logic where clinical breakthroughs meet commercial reality, where hospitals near-term challenges are discussed and translate into keeping the doors open, where healthcare leadership and their team can discover a revenue architecture that drives and sustains growth. Hosted by Eric Marr, this show is for the builders - founders, executives, clinicians, and innovators across home health, clinics, pharma, biotech, medtech, digital health, health systems, and rural hospitals. Each week, we break down the logic behind real healthcare growth. Not just the science - but the strategy. We explore go-to-market plays, market intelligence, and practical frameworks for navigating healthcare’s unique complexity. From ideation to clinical application to commercialization and adoption, we share hard-earned lessons from both failures and wins. CONNECT
.
| |||
| Priced to Win - How Small Life Science Companies Turn the MFN Drug Pricing Disruption Into a Commercial Advantage | 22 Jun 2026 | 00:28:07 | |
The MFN drug pricing framework - what began as voluntary agreements with sixteen of the largest pharmaceutical companies - is now moving toward mandatory rules that will reach smaller biotechs and pharma companies. At the same time, a 100% pharmaceutical tariff takes effect September 29th for smaller manufacturers, with a lower 20% rate available only to companies that have engaged the MFN framework and filed domestic manufacturing plans. BIO International opens at the same time of this published episode, June 22nd. So, in this episode, we flip the script: instead of treating MFN as a threat, we show small life science companies how to turn it into a commercial advantage - with five specific actions you can take starting this week.
Sources Referenced in This Episode: Skadden Arps — "MFN Drug Pricing and Impact on International Life Sciences Licensing Deals" — June 1, 2026 BioTech Briefings / Gibson Dunn — "MFN Drug Pricing in 2026: Voluntary Deals Are Giving Way to Mandatory Rules" — March 2026 Clinical Leader — "U.S. Pharma Tariffs and MFN Become Law After April 2 Update" — April 2026 AJMC — "MFN Drug Pricing Proposal Raises Questions Around Access, Innovation, and Commercial Coverage" — June 2026 BioSpace — "Despite MFN Deals, Drug Pricing Will Dog Pharma Into 2026" PharmExec — "What the Most Favored Nation Executive Order Means to Pharma Brands and Future Implications" — April 2026 BIO International Convention 2026 — San Diego, June 22–25, 2026 — convention.bio.org White House Council of Economic Advisers — "Savings from Most-Favored-Nation Drug Pricing Policy" — May 2026 About Life Science Logic: Life Science Logic is a commercial strategy consultancy serving small life science and healthcare companies. We help founders and operators build go-to-market strategies, competitive intelligence, and commercial plans with the clarity and rigor that early-stage companies deserve. Visit https://lifesciencelogic.com/ or reach us at Eric@lifesciencelogic.com.
Healthcare Logic for Growth · Life Science Logic · Eric@lifesciencelogic.com · © 2026 Life Science Logic | |||
| What Healthcare Startups Need to Do to Win - and Why So Many Fail | 29 Jun 2026 | 00:23:50 | |
In this episode of Healthcare Logic for Growth, we break down what healthcare startups need to do to succeed - and why so many fail. We cover the five biggest success factors, including solving a real problem, proving outcomes, building the payment model early, fitting into clinical workflows, and scaling with trust. We also look at five common failure patterns, including weak validation, no reimbursement path, long sales cycles, poor workflow fit, and trust breakdowns. We use real-world examples from Omada Health, Oshi Health, Zocdoc, Theranos, and Babylon Health to show what success and failure look like in practice. If you’re building, investing in, or marketing to healthcare startups, this episode is a practical guide to what actually matters. Key Topics - Why healthcare startups are different from consumer tech. - The five things a healthcare startup needs to do to succeed. - The five most common reasons healthcare startups fail. - Lessons from real companies with public-facing data. - Questions founders should ask to stay on track. - A go-forward strategy for building a durable healthcare company. Sources Referenced in This Episode: - AMA case study on Omada Health, highlighting evidence-based care, data-powered coaching, connected devices, and care coordination. - Omada public platform information on outcomes and care delivery. - AMA and related public materials on Oshi Health, including multidisciplinary GI care, outcomes, and cost savings. - Zocdoc’s public milestone update on profitability, cash flow, provider growth, and business model improvements. - STAT’s analysis of why healthcare startups fail, especially around reimbursement, pricing, and operational complexity. - Public materials on Theranos’s failures and regulatory issues. - Public reporting and analysis on Babylon Health’s collapse and reimbursement challenges. About Life Science Logic: Life Science Logic is a commercial strategy consultancy serving small life science and healthcare companies. We help founders and operators build go-to-market strategies, competitive intelligence, and commercial plans with the clarity and rigor that early-stage companies deserve. Visit https://lifesciencelogic.com/ or reach us at Eric@lifesciencelogic.com.
Healthcare Logic for Growth · Life Science Logic · Eric@lifesciencelogic.com · © 2026 Life Science Logic | |||
| The Digital Health Dichotomy - Who Gets Funded and Who Doesn’t | 27 Jul 2026 | 00:19:41 | |
In Q1 2026, nearly 60% of digital health investment went to just 12 mega-deals of $100 million or more. This episode breaks down what this funding concentration means for startups and smaller healthcare companies, and provides a practical go-forward strategy for navigating the new reality. Key Topics Covered:
Resources & Data Sources:
About Life Science Logic: Life Science Logic is a commercial strategy consultancy serving small life science and healthcare companies. We help founders and operators build go-to-market strategies, competitive intelligence, and commercial plans with the clarity and rigor that early-stage companies deserve. Visit https://lifesciencelogic.com/ or reach us at Eric@lifesciencelogic.com. Disclaimer: The information provided in this podcast is for educational and informational purposes only and does not constitute legal, financial, or regulatory advice. Always consult with qualified professionals regarding your specific situation.
Healthcare Logic for Growth · Life Science Logic · Eric@lifesciencelogic.com · © 2026 Life Science Logic | |||
| For Digital Health Firms - Providing Clinical Value, Not Just Engagement Metrics Is Critical | 20 Jul 2026 | 00:18:06 | |
In this episode of Healthcare Logic for Growth, we talked about why digital health companies must prove clinical value, not just engagement. We covered why activity metrics like downloads and retention are no longer enough on their own, why investors and health systems want stronger evidence, and why startups often struggle to generate proof within limited runway. We also walked through a practical go-forward strategy for defining the outcome you need to prove, matching evidence to the buyer, limiting metrics, and connecting proof to adoption. Finally, we briefly discussed how Life Science Logic helps companies think through the path from product to proof to commercialization through GTM Sprint, GTM Crossroads, CIB, Advisory Services, and Commercialization Services. Resources: We looked at a PubMed article, “Applying Evidence-Based Medicine Standards to Digital Tools,” which argues that digital health tools should meet evidence expectations similar to other clinical interventions. pubmed.ncbi.nlm.nih We also reviewed the Lancet Digital Health article, “Advancing digital health applications: priorities for innovation in real-world evidence generation,” which discusses the importance of real-world evidence in digital medicine. thelancet Another important source was the npj Digital Medicine article, “Digital therapeutics from bench to bedside,” which covers the role of real-world evidence, commercialization, and barriers to broader adoption. nature We also referenced a digital health commercialization framework from MIT, which helps support the broader strategy discussion.dspace.mit+1 And we looked at a recent Healthcare Logic for Growth episode that focused on what healthcare startups need to do to win, including proving outcomes, fitting workflow, and building the payment model early. Published on Spotify, Apple Podcasts, iHeart Rdio and YT And lastly, we used the Life Science Logic Intelligence Engine, our internal life sciences AI, to help synthesize the evidence and sharpen the strategic takeaways for this episode. Have a question or topic you'd like us to cover? Reach out to us at eric@lifesciencelogic.com About Life Science Logic: Life Science Logic is a commercial strategy consultancy serving small life science and healthcare companies. We help founders and operators build go-to-market strategies, competitive intelligence, and commercial plans with the clarity and rigor that early-stage companies deserve. Visit https://lifesciencelogic.com/ or reach us at Eric@lifesciencelogic.com. Disclaimer: The information provided in this podcast is for educational and informational purposes only and does not constitute legal, financial, or regulatory advice. Always consult with qualified professionals regarding your specific situation.
Healthcare Logic for Growth · Life Science Logic · Eric@lifesciencelogic.com · © 2026 Life Science Logic | |||
| Home Is the New Site of Care: Why Home-Based Growth Depends on Design Not Just Demand | 13 Jul 2026 | 00:14:45 | |
Why growing in home health care requires a new staffing, reimbursement, and service design model—and what small agencies need to check before accepting new referrals. Key Topics:
Go Forward Strategy - 5 Actions:
Resource Mentioned: Building A Potential Tool for Home-Based Care Margin Mapping (based on 10-15 followers or subscriptions)
Follow & Subscribe: Don't miss an episode! Subscribe to Healthcare Logic for Growth on wherever you get your podcasts. Apple Podcasts: https://podcasts.apple.com/us/podcast/healthcare-logic-for-growth/id1890160182 Spotify: https://open.spotify.com/show/1YSwyajbIWDkVWwrIPM1j3 YouTube: https://www.youtube.com/@HealthcareLogicforGrowth
Have a question or topic you'd like us to cover? Reach out to us at eric@lifesciencelogic.com About Life Science Logic: Life Science Logic is a commercial strategy consultancy serving small life science and healthcare companies. We help founders and operators build go-to-market strategies, competitive intelligence, and commercial plans with the clarity and rigor that early-stage companies deserve. Visit https://lifesciencelogic.com/ or reach us at Eric@lifesciencelogic.com. Disclaimer: The information provided in this podcast is for educational and informational purposes only and does not constitute legal, financial, or regulatory advice. Always consult with qualified professionals regarding your specific situation.
Healthcare Logic for Growth · Life Science Logic · Eric@lifesciencelogic.com · © 2026 Life Science Logic | |||
| What we've learned in the 1st 6 months of 2026 | 06 Jul 2026 | 00:22:13 | |
In this episode of Healthcare Logic for Growth, we break down the pivotal trends from the first half of 2026 that every small and start-up healthcare company needs to know. We explore the good news (rebounding venture funding, FDA fast-track vouchers, and digital health pilot programs), the bad news (FDA staffing shortages, drug pricing uncertainty, and OMB grant threats), and the "data trap" catch-22 that is stifling early-stage biotechs. We share 10 actionable steps to help you navigate the next six months with confidence. Sources Referenced in This Episode: - HSBC Innovation Banking – US Healthcare Venture Investment Report: Provided the $60 billion funding data and the trend of investors demanding later-stage traction from seed-stage companies. - PharmaVoice – Life Sciences 2026 Outlook & FDA Staffing Analysis: Sourced the quotes on FDA staffing challenges post-DOGE and the uncertainty surrounding political appointees at the agency. - FDA Official Guidance & Pilot Programs (2026): - Commissioner’s National Priority Voucher Program (Fast-track review). - TEMPO Pilot Program (Enforcement discretion for digital health technologies). - Revised Guidance on Low-Risk Wellness & Clinical Decision Support Software. - CMS – ACCESS Model Demonstration: Source for the outcomes-based reimbursement model for digital health and medical devices. - Federal Register / OMB – Proposed Rule on Grant Cancellations (May 2026): Source for the non-scientific criteria clause affecting SBIR and NIH grants. - White House Executive Orders – Most Favored Nation Pricing & IRA Implementation Updates: Source for drug pricing pressures. - Congressional Bills – Biotech Workforce Development & Biosecure Act: Source for talent pipeline initiatives and supply chain manufacturing restrictions. - Industry Venture Capital Panel Discussions (Q1/Q2 2026) – various: Sourced the "ship at 92%" mentality and the commercial leadership cautionary tale. Follow & Subscribe: Don't miss an episode! Subscribe to Healthcare Logic for Growth on wherever you get your podcasts. Apple Podcasts: https://podcasts.apple.com/us/podcast/healthcare-logic-for-growth/id1890160182 Spotify: https://open.spotify.com/show/1YSwyajbIWDkVWwrIPM1j3 YouTube: https://www.youtube.com/@HealthcareLogicforGrowth
Have a question or topic you'd like us to cover? Reach out to us at eric@lifesciencelogic.com About Life Science Logic: Life Science Logic is a commercial strategy consultancy serving small life science and healthcare companies. We help founders and operators build go-to-market strategies, competitive intelligence, and commercial plans with the clarity and rigor that early-stage companies deserve. Visit https://lifesciencelogic.com/ or reach us at Eric@lifesciencelogic.com. Disclaimer: The information provided in this podcast is for educational and informational purposes only and does not constitute legal, financial, or regulatory advice. Always consult with qualified professionals regarding your specific situation.
Healthcare Logic for Growth · Life Science Logic · Eric@lifesciencelogic.com · © 2026 Life Science Logic | |||
| RHTP in Texas: Inside the State with the Most Rural Hospitals on the Brink. | 10 Aug 2026 | 00:18:10 | |
In this episode we cover: Texas has more at-risk rural hospitals than any other state in the country — and the $50 billion Rural Health Transformation Program just arrived to try to change that. We break down what Rural Texas Strong actually funds, and why the math doesn't yet match the scale of the crisis.
Key Topics: 01 Texas has the most at-risk rural hospitals (50) of any U.S. state 02 What the Rural Health Transformation Program (RHTP) is and how Rural Texas Strong is structured 03 Why 281 million dollars a year doesn't match the scale of the underlying crisis 04 The gap between "announced" funding and funding that's actually reaching hospitals
Go Forward Strategy — 5 Actions: 01 Get your own Texas exposure number this week 02 Bookmark the Rural Texas Strong initiative list, not just the headline 03 Separate "announced" from "available" 04 Watch your customers' payer mix, not just the RHTP headline 05 Start following this series as a system, not a one-off
Next Episode: The RHTP Math Problem: Why $281 Million a Year Won't Fix Texas Rural Hospitals' Margins (Episode 2 of the RHTP Series) About Life Science Logic: Life Science Logic is a commercial strategy consultancy serving small life science and healthcare companies. We help founders and operators build go-to-market strategies, competitive intelligence, and commercial plans with the clarity and rigor that early-stage companies deserve. Visit https://lifesciencelogic.com/ or reach us at Eric@lifesciencelogic.com. Disclaimer: The information provided in this podcast is for educational and informational purposes only and does not constitute legal, financial, or regulatory advice. Always consult with qualified professionals regarding your specific situation.
Healthcare Logic for Growth · Life Science Logic · Eric@lifesciencelogic.com · © 2026 Life Science Logic | |||
| Reimbursement - The Hidden Roadblock | 03 Aug 2026 | 00:21:25 | |
Too many healthcare companies build the product before mapping the reimbursement pathway. And that mismatch - between clinical value and commercial reality - is what stalls otherwise good businesses. The market is only getting less forgiving of that gap. The fix requires discipline: map the pathway, identify the real buyer, build evidence for that buyer specifically, and sequence your commercialization plan around the path to payment - not just the path to launch. Resources & Data Sources:
About Life Science Logic: Life Science Logic is a commercial strategy consultancy serving small life science and healthcare companies. We help founders and operators build go-to-market strategies, competitive intelligence, and commercial plans with the clarity and rigor that early-stage companies deserve. Visit https://lifesciencelogic.com/ or reach us at Eric@lifesciencelogic.com. Disclaimer: The information provided in this podcast is for educational and informational purposes only and does not constitute legal, financial, or regulatory advice. Always consult with qualified professionals regarding your specific situation.
Healthcare Logic for Growth · Life Science Logic · Eric@lifesciencelogic.com · © 2026 Life Science Logic | |||